Menu
Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. The company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. Glaukos launched the iStent, its first MIGS device, in the United States in 2012, its next-generation iStent inject device in the United States in 2018, and most recently, the iStent inject W device in 2020. In corneal health, Glaukos' proprietary suite of single-use, bio-activated pharmaceuticals are designed to strengthen, stabilize and reshape the cornea through a process called corneal collagen cross-linking to treat corneal ectatic disorders and correct refractive conditions. Glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale surgical and pharmaceutical therapies in glaucoma, corneal health and retinal disease.
229 Avenida Fabricante
San Clemente, California 92672-7531
Phone: 19493679600
www.glaukos.com
BOSTON , Sept. 15, 2023 /PRNewswire/ -- Below is the August 2023 Monthly Update for the Liberty All-Star Growth Fund, Inc. (NYSE: ASG ) Liberty All-Star Growth Fund, Inc. Ticker: ASG Monthly Update, August, 2023 Investment Approach: Fund Style: All-Cap Growth Fund Strategy: Combines three growth style investment managers, each with a distinct capitalization focus (small-, mid- and large-cap) selected and continuously monitored by the Fund''s Investment Advisor. Investment Managers: Weatherbie Capital, LLC Small-Cap Growth Congress Asset Management Company, LLP Mid-Cap Growth Sustainable Growth Advisers, LP Large-Cap Growth Top 20 Holdings at Month-End (32.8% of equity portfolio) 1 SPS Commerce, Inc. 2.5 % 2 Microsoft Corp. 2.2 % 3 Amazon.com, Inc. 2.1 % 4 Visa, Inc. 1.9 % 5 Flywire Corp. 1.8 % 6 FirstService Corp. 1.8 % 7 Glaukos Corp. 1.7 % 8 Progyny, Inc. 1.7 % 9 SiteOne Landscape Supply, Inc. 1.6 % 10 Workday, Inc. … Full story available on Benzinga.com
Bank of New York Mellon Corp trimmed its stake in shares of Glaukos Co. (NYSE:GKOS – Free Report) by 2.1% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 440,509 shares of the medical instruments supplier’s stock after selling 9,500 shares during the quarter. Bank […]
Glaukos Corporation (NYSE:NYSE:GKOS) Q2 2023 Earnings Conference Call August 2, 2023 4:30 PM ETCompany ParticipantsChristopher Lewis - VP, IR & Corporate AffairsThomas Burns - Chairman…
Texas Permanent School Fund Corp grew its position in shares of Glaukos Co. (NYSE:GKOS – Free Report) by 33.4% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 42,780 shares of the medical instruments supplier’s stock after acquiring an additional 10,710 […]